rgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of bridging antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. - Tirofiban for urgent surgery aftercoronary stent

AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2009年9月18日最近更新: 2012年4月18日

适应症

试验速览

暂无简介。

•The study involves consecutive candidates for urgent major surgery or eye surgery in whom dual antiplatelet therapy cannot be withdrawn because they had received a drug eluting stent within the previous six months, or within the previous year if they are considered to be at higher risk of developing stent thrombosis because of stent implantation due to an acute coronary syndrome, diabetes, renal insufficiency, severe left ventricular dysfunction, malignancy, or in the left main coronary artery, the proximal segment of the left anterior descending artery (or equivalent in the case of a stent in an aortocoronary graft), or on a coronary bifurcation. The patients also are to be at such a risk of surgical bleeding that the surgeon would not operate while the patient was receiving clopidogrel.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Excluded are patients with ongoing severe bleeding requiring emergency surgery (within 24 hours of hospital admission), those with thrombocytopenia <100.000 x 10-9/L, a stroke within the previous 30 days or a history of hemorrhagic stroke, intracranial disease or bleeding diathesis, severe hypertension, and those unwilling or unable to sign the informed consent form.

发起方

AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE)